Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN Trial

NCT05355350 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT05355350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05355350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN Trial
Lead sponsor
Rambam Health Care Campus
Phase
Phase 4
Overall status
Withdrawn
Start date
July 1, 2022
Completion date
July 21, 2025
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia, beta lactam resistant bacterial infection, enterobacteriaceae infections